Alfredo G Casanova1,2,3,4, María Teresa Hernández-Sánchez1,2,3,4, Francisco J López-Hernández1,2,3,4, Carlos Martínez-Salgado1,2,3,4, Marta Prieto1,2,3,4, Laura Vicente-Vicente5,6,7,8, Ana Isabel Morales1,2,3,4. 1. Unidad de Toxicología, Departamento de Fisiología y Farmacología, University of Salamanca, Laboratorio 223-226, Campus Miguel de Unamuno, 37007, Salamanca, Spain. 2. Instituto de Investigación Biomédica de Salamanca (IBSAL)-Instituto de Estudios de Ciencias de la Salud de Castilla y León (IESCYL), Salamanca, Spain. 3. Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), Salamanca, Spain. 4. Grupo de Investigación Biomédica en Cuidados Críticos (BioCritic), Valladolid, Spain. 5. Unidad de Toxicología, Departamento de Fisiología y Farmacología, University of Salamanca, Laboratorio 223-226, Campus Miguel de Unamuno, 37007, Salamanca, Spain. lauravicente@usal.es. 6. Instituto de Investigación Biomédica de Salamanca (IBSAL)-Instituto de Estudios de Ciencias de la Salud de Castilla y León (IESCYL), Salamanca, Spain. lauravicente@usal.es. 7. Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), Salamanca, Spain. lauravicente@usal.es. 8. Grupo de Investigación Biomédica en Cuidados Críticos (BioCritic), Valladolid, Spain. lauravicente@usal.es.
Abstract
INTRODUCTION: Cisplatin is a potent antineoplastic drug that has been widely used to treat a number of solid tumors. However, a high incidence of renal damage observed in patients has led researchers to search for alternate strategies that prevent or at least reduce the cisplatin-induced nephrotoxicity. The objective of the present study was to conduct a systematic review and a subsequent meta-analysis to evaluate and identify compounds with effective antitumor activity and lesser side effects that could provide protection against cisplatin-induced nephrotoxicity. METHODS: The study included all placebo-controlled trials published up to December 2017 that met the inclusion criteria. A total of 22 articles were finally included to extract the following information: number of patients, doses of cisplatin and protectant, qualitative (acute kidney injury incidence) and quantitative (plasma creatinine, blood urea nitrogen, and creatinine clearance) indicators of renal function. The odds ratio or the mean difference (95% confidence interval) of each parameter was calculated for each study and group of studies. RESULTS: The results of this meta-analysis show that there is great variability in the nephroprotective capacity of a variety of products evaluated. Of all the compounds tested, only magnesium sulfate and cystone were found to exert protective effects. However, more studies need to be conducted to confirm these results. CONCLUSIONS: The administration of 1 g of Mg i.v. seems to be the best strategy for the prevention of cisplatin nephrotoxicity.
INTRODUCTION:Cisplatin is a potent antineoplastic drug that has been widely used to treat a number of solid tumors. However, a high incidence of renal damage observed in patients has led researchers to search for alternate strategies that prevent or at least reduce the cisplatin-induced nephrotoxicity. The objective of the present study was to conduct a systematic review and a subsequent meta-analysis to evaluate and identify compounds with effective antitumor activity and lesser side effects that could provide protection against cisplatin-induced nephrotoxicity. METHODS: The study included all placebo-controlled trials published up to December 2017 that met the inclusion criteria. A total of 22 articles were finally included to extract the following information: number of patients, doses of cisplatin and protectant, qualitative (acute kidney injury incidence) and quantitative (plasma creatinine, blood ureanitrogen, and creatinine clearance) indicators of renal function. The odds ratio or the mean difference (95% confidence interval) of each parameter was calculated for each study and group of studies. RESULTS: The results of this meta-analysis show that there is great variability in the nephroprotective capacity of a variety of products evaluated. Of all the compounds tested, only magnesium sulfate and cystone were found to exert protective effects. However, more studies need to be conducted to confirm these results. CONCLUSIONS: The administration of 1 g of Mg i.v. seems to be the best strategy for the prevention of cisplatinnephrotoxicity.
Authors: Habib T E Karakoc; Ramazan Altintas; Hakan Parlakpinar; Alaaddin Polat; Emine Samdanci; Mustafa Sagir; Zeynep R Duran Journal: Adv Clin Exp Med Date: 2015 Jul-Aug Impact factor: 1.727
Authors: Di Maria Jiang; Shilpa Gupta; Abhijat Kitchlu; Alejandro Meraz-Munoz; Scott A North; Nimira S Alimohamed; Normand Blais; Srikala S Sridhar Journal: Nat Rev Urol Date: 2021-01-11 Impact factor: 14.432
Authors: Mohammed Al Za'abi; Haytham Ali; Mohammed Al Sabahi; Badreldin H Ali Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2021-05-18 Impact factor: 3.000
Authors: Alfredo G Casanova; Marta Prieto; Clara I Colino; Carmen Gutiérrez-Millán; Barbara Ruszkowska-Ciastek; Esther de Paz; Ángel Martín; Ana I Morales; Francisco J López-Hernández Journal: Int J Mol Sci Date: 2021-01-13 Impact factor: 5.923
Authors: Mary Elizabeth Money; Aghiles Hamroun; Yan Shu; Carolyn Matthews; Sara Ahmed Eltayeb; Giuliano Ciarimboli; Christine Noel Metz Journal: Front Oncol Date: 2021-02-26 Impact factor: 6.244
Authors: Muhammad Omer Iqbal; Asad Saleem Sial; Imran Akhtar; Muhammad Naeem; Abu Hazafa; Rais A Ansari; Syed A A Rizvi Journal: Bioengineered Date: 2021-12 Impact factor: 3.269